Here, ERBB2 amplified tumors had one of the highest median TMBs (10.9 mut/Mb) compared to all other guideline-recommended oncogenic driver genes and ERBB2 Y772-A775dup (5 mut/Mb) (Figure 2F), the most frequent ERBB2 mutation found in NSCLC tumors. This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.